Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study

GREEN (NCT01905943) is a non-randomized, open-label phase IIIb study investigating obinutuzumab alone or plus chemotherapy in chronic lymphocytic leukemia (CLL). We report a preplanned subgroup analysis of 158 previously untreated CLL patients receiving obinutuzumab–bendamustine (G-B). Patients rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Stilgenbauer, Stephan, Leblond, Veronique, Foà, Robin, Böttcher, Sebastian, Ilhan, Osman, Knauf, Wolfgang, Mikuskova, Eva, Renner, Christoph, Tausch, Eugen, Woszczyk, Dariusz, Gresko, Ekaterina, Lundberg, Linda, Moore, Tom, Morris, Thea, Robson, Susan, Bosch, Francesc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087718/
https://www.ncbi.nlm.nih.gov/pubmed/29749403
http://dx.doi.org/10.1038/s41375-018-0146-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087718/
https://www.ncbi.nlm.nih.gov/pubmed/29749403
http://dx.doi.org/10.1038/s41375-018-0146-5

Ejemplares similares